A new publication from collaborators at Radboud University Medical Center, published in Advanced Healthcare Materials, reinforces the importance of cellular phenotype and durability in adoptive cell therapy.
The study underscores a critical insight in adoptive cell therapy: product quality — including phenotype and functional characteristics — may outweigh total cell count in driving durable clinical responses.
The researchers demonstrate that optimizing stimulation conditions to preserve early memory and less differentiated T cells can improve long-term therapeutic potential.
Importantly, the addition of IL-2 increased terminal effector populations and markers associated with exhaustion and regulatory T cells, which may compromise long-term efficacy.
This work aligns with a broader shift in the field toward quality-driven manufacturing strategies — not merely maximizing cell yield, but enhancing functional durability and therapeutic impact.
Congratulations to the authors on this important contribution.